» Articles » PMID: 38133336

Evolving Clinical Manifestations and Outcomes in COVID-19 Patients: A Comparative Analysis of SARS-CoV-2 Variant Waves in a Romanian Hospital Setting

Overview
Journal Pathogens
Date 2023 Dec 22
PMID 38133336
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of this study was to evaluate differences in the clinical manifestations and outcomes in hospitalized patients with COVID-19 in a single Romanian center during four pandemic waves determined by different SARS-CoV-2 variants of concern (VOCs). A retrospective study on 9049 consecutive hospitalized adult patients was performed between 27 February 2020 and 31 March 2023. The study interval was divided into waves based on national data on SARS-CoV-2 VOCs' circulation. Multivariate logistic regression models were built, predicting death and complications as functions of comorbidities, therapy, wave, severity form, and vaccination status, and adjusted for ages ≥65 years. Pulmonary (pneumothorax/pneumomediastinum, pulmonary embolism) and extrapulmonary complications (liver injury, acute kidney injury, ischemic/hemorrhagic stroke, myocardial infarction, and gastrointestinal bleeding) were present, more frequently in ICU hospitalized patients and with differences between waves. The highest in-hospital mortality was found in patients presenting pneumothorax/pneumomediastinum. All of the evaluated risk factors were significantly associated with death, except for obesity and the Omicron wave. Our study highlights the changing nature of COVID-19 and acknowledges the impacts of viral mutations on disease outcomes. For all four waves, COVID-19 was a severe disease with a high risk of poor outcomes.

Citing Articles

Complexity and Diversity of the Neurological Spectrum of SARS-CoV-2 over Three Waves of COVID-19.

Jachman-Kapulka J, Zinczuk A, Szymanski W, Simon K, Rorat M J Clin Med. 2024; 13(12).

PMID: 38930003 PMC: 11204600. DOI: 10.3390/jcm13123477.


Effects of COVID-19 on the Liver and Mortality in Patients with SARS-CoV-2 Pneumonia Caused by Delta and Non-Delta Variants: An Analysis in a Single Centre.

Muntean M, Briciu V, Lupse M, Colcear D, Macicasan R, Csiszer A Pharmaceuticals (Basel). 2024; 17(1).

PMID: 38275989 PMC: 10820137. DOI: 10.3390/ph17010003.

References
1.
Alghamdi Z, Alqahtani S, AlDajani K, Alsaedi A, Al-Rubaish O, Alharbi A . Pneumothorax in Critically Ill COVID-19 Patients: Prevalence, Analysis of Risk Factors and Clinical Outcomes. Int J Gen Med. 2022; 15:8249-8256. PMC: 9698325. DOI: 10.2147/IJGM.S387868. View

2.
Radulescu A, Istrate A, Muntean M . Treatment with Tocilizumab in Adult Patients with Moderate to Critical COVID-19 Pneumonia: A Single-Center Retrospective Study. Int J Infect Dis. 2022; 117:1-7. PMC: 8793111. DOI: 10.1016/j.ijid.2022.01.048. View

3.
Zellmer S, Hanses F, Muzalyova A, Classen J, Braun G, Piepel C . Gastrointestinal bleeding and endoscopic findings in critically and non-critically ill patients with corona virus disease 2019 (COVID-19): Results from Lean European Open Survey on SARS-CoV-2 (LEOSS) and COKA registries. United European Gastroenterol J. 2021; 9(9):1081-1090. PMC: 8598966. DOI: 10.1002/ueg2.12165. View

4.
King A, Vail A, OLeary C, Hannan C, Brough D, Patel H . Anakinra in COVID-19: important considerations for clinical trials. Lancet Rheumatol. 2020; 2(7):e379-e381. PMC: 7241987. DOI: 10.1016/S2665-9913(20)30160-0. View

5.
Matsumoto K, Prowle J . COVID-19-associated AKI. Curr Opin Crit Care. 2022; 28(6):630-637. PMC: 9612421. DOI: 10.1097/MCC.0000000000000988. View